Novavax, Inc. (NVAX), the orignal swine flu momentum stock, is rising today ( $2.60 ) on follow up news on their H1N1 vaccine. Discuss NVAX - Discuss stocks - http://stockstobuy.org
Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate against the Novel Influenza A (H1N1) Virus
Company completes initial steps towards producing Influenza A (H1N1) VLP vaccine
for animal and human testing
Novavax, Inc. (NASDAQ: NVAX) and the Division of Microbiology and Infectious Diseases (DMID) of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) have signed an agreement to cooperate in the evaluation of a virus-like particle (VLP) vaccine candidate against the novel influenza A (H1N1) virus. Novavax has produced influenza A (H1N1) VLP vaccine against the strain recommended by the Centers for Disease Control and Prevention (CDC).
http://www.novavax.com/download/releases/H1N1FO21.pdf
For More Stock Market Updates, visit , http://daytradingstockblog.blogspot.com/ or Subscribe for FREE